At the heart of the ruling are the "marketing and promotion" of the drugs that "created a nuisance" as defined by law. As the penalty was smaller than some anticipated, the company's stock rose shortly after it was handed down. Johnson & Johnson plans to appeal the ruling.
Read the full article from CNBC.